Gilead Sciences, Inc. (NASDAQ:GILD) hasn’t been able to bring a smile on the investors’ faces throughout the first three quarters of 2016, and in the last quarter as well, the company did not break the ice. Following the downward trend, the company announced its Q4 2016 results recently, and...
Galena Biopharma Inc (NASDAQ:GALE) a biopharmaceutical firm committed to the advancement and commercialization of hematology as well as oncology therapeutics issued the report from a meeting of the DSMB for the two IST combination clinical studies with NeuVax™ plus trastuzumab. The studies are being carried out in breast cancer...
The stock price of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) are moving north on the chart since last few days. Recent NASH play has finally rewarded firm’s shareholders. The biotech concern has made a transformational collaboration agreement with drug giant company Novartis AG (ADR)(NYSE:NVS) about its compound emricasan.
The biotech industry continues...
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stated that, subsequent to an autonomous DSMB recommendation and also following futility assessment, it has halted the Phase II HERMIONE trial of “MM-302” in people suffering with +HER2 metastatic breast cancer, but had initially been on regimen of pertuzumab, trastuzumab and ado-trastuzumab emtansine.
The buzz
The decision...
Heat Biologics Inc (NASDAQ:HTBX) recently said that the survival results and top-line response of Phase 1b study evaluating lung cancer treatment with Bristol-Myers Squibb’s drug showed positive signs. The company reported HS-110/Nivolumab Combination for treating non-small cell lung cancer (NSCLC) in Austria at International Association for the Study of...
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) inked an alliance agreement with Novartis for development of their lead product, a drug called emricasan. The transaction was done with an upfront cost of $50 million and around $650 million to be paid in milestone payments in the times to come.
Novartis gets emricasan’s rights...
Aducanumab, a clinical treatment drug, primed to treat those with early symptoms of Alzheimer’s, recently went into Phase 1B clinical studies trial. Recently, the firm responsible for the manufacturing of the clinical treatment drugs, Biogen Inc. (NASDAQ:BIIB) released the data obtained from the Phase 1B trial.
The data will be...
Dallas, Texas 04/28/2014 (FINANCIALSTRENDS) – Prana Biotechnology Limited (ADR)(NASDAQ:PRAN) has in the past week announced the results of the top-line results after the company declared its ‘12-month Phase II imaging trails’ as part of its Alzheimer’s disease solution matrix.
With several companies vying for top drug or therapy to resolve age-related problems...
Dallas, Texas 04/03/2014 (FINANCIALSTRENDS) – iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) has been on the top for quite a long time now and recently has taken a U-turn and is heading on a downward spiral. This sudden fall was seen after 17th March when the Democrats' who were attending the...